A survey last fall by Natixis Investment Managers found that 74% of institutional money managers expect a market correction in 2026. They cited various reasons, from the tech bubble bursting to geopolitics and macroeconomic factors. Currently, the Nasdaq Composite is hovering around even year to date, while the S&P 500 has risen roughly 1.7%.
Corrections are part of the investment landscape. We had one last year, and there have been eight corrections or bear markets over the past 10 years.
Will AI create the world’s first trillionaire? Our team just released a report on the one little-known company, called an “Indispensable Monopoly” providing the critical technology Nvidia and Intel both need. Continue »
While you can’t avoid them, you can prepare for them with stocks designed to zig when the market zags. Here are two within the healthcare sector that may help you do that.
Two pharmaceutical giants, AbbVie (NYSE: ABBV) and Merck (NYSE: MRK), have more in common than just manufacturing drugs. They are both terrific defensive stocks. That means they make products that are in demand in all cycles, because they’re just as critical in a downturn as they are in a bull market. However, their effect on a portfolio is much more pronounced during a downturn, when growth stocks tend to struggle.
In the last few down cycles, both AbbVie and Merck stocks soared. In the 2022 bear market, AbbVie stock jumped 24% for the year, while Merck surged 49%. That year, the S&P 500 finished down 18%. In 2018, when the S&P 500 dropped 4%, AbbVie was down 1%, and Merck rose 40%.
On the other hand, both stocks do tend to underperform in years when the overall markets are strong. But the long-term numbers are generally in line with the S&P 500. They just don’t move in tandem with the large-cap benchmark. AbbVie stock has an average annualized return of 15% over the past 10 years, while Merck is at 10%. For comparison, the S&P 500 has a 10-year annualized return of 14%.
A hallmark of a good defensive stock is its dividend, and both AbbVie and Merck offer robust dividends.
AbbVie just raised its dividend last month by 5% to $1.73 per share at a yield of 3.10%. This is the 13th consecutive year that it has increased its dividend — something it has done every year since it spun off from Abbott Laboratories in 2013.
Merck pays out a quarterly dividend of $0.85 per share at a yield of 2.99%. Like AbbVie, its yield is some three times the S&P 500 average yield of 1.13%. It has raised its dividend for 15 years in a row.
